

NCPE Annual Symposium 2025



Join us for our Annual Symposium on **16th October 2025** at the **Cusack Suite, Croke Park**.

Visit the **NCPE website** to register.

Completed Rapid Reviews



- Selpercatinib (Retsevmo®) for advanced RET-mutant medullary thyroid cancer. HTA ID: 25034a
- Selpercatinib (Retsevmo®) for advanced RET fusion-positive thyroid cancer. HTA ID: 25034b
- Glofitamab (Columvi®) for DLBCL. HTA ID 25037
- Trastuzumab Deruxtecan (Enhertu®). HTA ID: 25039
- Acalabrutinib (Calquence®) for CLL. HTA ID: 25040
- Acalabrutinib (Calquence®) for MCL. HTA ID: 25041
- Bevacizumab gamma (Lytenava®). HTA ID:25043

Completed HTAs



- Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) for hepatocellular carcinoma. HTA ID: 23073
- Anifrolumab (Saphnelo®) for systemic lupus erythematosus. HTA ID: 23027

Stay Informed



Keep updated with NCPE's initiatives at www.ncpe.ie